JP3348156B2 - 組換えアビポックスウィルス - Google Patents

組換えアビポックスウィルス

Info

Publication number: JP3348156B2
Authority: JP; Japan
Prior art keywords: virus; promoter; gene; recombinant; site
Prior art date: 1987-08-28
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

JP50771588A

Other languages

English (en)

Japanese (ja)

Other versions

JPH02500879A (ja

Inventor

パオレッティ、アンツオ

Original Assignee

ヘルス・リサーチ・インク

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1987-08-28

Filing date

1988-08-24

Publication date

2002-11-20

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27492413&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP3348156(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1988-08-24 Application filed by ヘルス・リサーチ・インク filed Critical ヘルス・リサーチ・インク

1990-03-29 Publication of JPH02500879A publication Critical patent/JPH02500879A/ja

2002-11-20 Application granted granted Critical

2002-11-20 Publication of JP3348156B2 publication Critical patent/JP3348156B2/ja

2017-11-20 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

241000700663 Avipoxvirus Species 0.000 title claims description 44
241000700605 Viruses Species 0.000 claims description 128
206010037742 Rabies Diseases 0.000 claims description 65
239000000427 antigen Substances 0.000 claims description 53
108091007433 antigens Proteins 0.000 claims description 53
102000036639 antigens Human genes 0.000 claims description 53
238000000034 method Methods 0.000 claims description 51
238000011081 inoculation Methods 0.000 claims description 48
206010046865 Vaccinia virus infection Diseases 0.000 claims description 45
208000007089 vaccinia Diseases 0.000 claims description 45
241000714165 Feline leukemia virus Species 0.000 claims description 29
241000700662 Fowlpox virus Species 0.000 claims description 29
230000028993 immune response Effects 0.000 claims description 27
244000052769 pathogen Species 0.000 claims description 19
241000124008 Mammalia Species 0.000 claims description 17
230000001717 pathogenic effect Effects 0.000 claims description 12
241000700584 Simplexvirus Species 0.000 claims description 8
241000178270 Canarypox virus Species 0.000 claims description 6
241001135961 Amsacta moorei entomopoxvirus Species 0.000 claims description 4
230000001939 inductive effect Effects 0.000 claims description 4
101000678879 Homo sapiens Atypical chemokine receptor 1 Proteins 0.000 claims description 3
102100022717 Atypical chemokine receptor 1 Human genes 0.000 claims description 2
101500007117 Bovine leukemia virus Surface protein Proteins 0.000 claims 1
102000002322 Egg Proteins Human genes 0.000 claims 1
108010000912 Egg Proteins Proteins 0.000 claims 1
210000004681 ovum Anatomy 0.000 claims 1
108090000623 proteins and genes Proteins 0.000 description 133
239000013612 plasmid Substances 0.000 description 132
239000012634 fragment Substances 0.000 description 102
210000004027 cell Anatomy 0.000 description 66
241000287828 Gallus gallus Species 0.000 description 65
235000013330 chicken meat Nutrition 0.000 description 65
102000053602 DNA Human genes 0.000 description 47
108020004414 DNA Proteins 0.000 description 46
239000013598 vector Substances 0.000 description 44
241000271566 Aves Species 0.000 description 36
238000003780 insertion Methods 0.000 description 36
230000037431 insertion Effects 0.000 description 36
108010054576 Deoxyribonuclease EcoRI Proteins 0.000 description 33
208000000666 Fowlpox Diseases 0.000 description 31
108091034117 Oligonucleotide Proteins 0.000 description 31
241000700618 Vaccinia virus Species 0.000 description 31
229960005486 vaccine Drugs 0.000 description 31
241000283973 Oryctolagus cuniculus Species 0.000 description 30
230000014509 gene expression Effects 0.000 description 30
210000002966 serum Anatomy 0.000 description 30
241000251539 Vertebrata <Metazoa> Species 0.000 description 26
208000015181 infectious disease Diseases 0.000 description 26
230000006798 recombination Effects 0.000 description 26
239000000047 product Substances 0.000 description 25
102000004169 proteins and genes Human genes 0.000 description 25
101710154606 Hemagglutinin Proteins 0.000 description 24
101710093908 Outer capsid protein VP4 Proteins 0.000 description 24
101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 24
101710176177 Protein A56 Proteins 0.000 description 24
238000002360 preparation method Methods 0.000 description 23
238000012360 testing method Methods 0.000 description 23
108091026890 Coding region Proteins 0.000 description 22
241001465754 Metazoa Species 0.000 description 22
238000005215 recombination Methods 0.000 description 21
239000000185 hemagglutinin Substances 0.000 description 20
101150082239 G gene Proteins 0.000 description 19
238000011144 upstream manufacturing Methods 0.000 description 19
230000004044 response Effects 0.000 description 18
238000002474 experimental method Methods 0.000 description 17
238000000338 in vitro Methods 0.000 description 17
239000011159 matrix material Substances 0.000 description 17
108090000288 Glycoproteins Proteins 0.000 description 16
241000711450 Infectious bronchitis virus Species 0.000 description 16
108700004025 env Genes Proteins 0.000 description 16
101150030339 env gene Proteins 0.000 description 16
102000003886 Glycoproteins Human genes 0.000 description 15
241000714266 Bovine leukemia virus Species 0.000 description 14
102000004594 DNA Polymerase I Human genes 0.000 description 14
108010017826 DNA Polymerase I Proteins 0.000 description 14
230000029087 digestion Effects 0.000 description 14
239000002773 nucleotide Substances 0.000 description 14
125000003729 nucleotide group Chemical group 0.000 description 14
241000894007 species Species 0.000 description 13
238000013518 transcription Methods 0.000 description 13
230000035897 transcription Effects 0.000 description 13
108010005774 beta-Galactosidase Proteins 0.000 description 12
238000004519 manufacturing process Methods 0.000 description 12
238000002255 vaccination Methods 0.000 description 12
241000699670 Mus sp. Species 0.000 description 11
230000000890 antigenic effect Effects 0.000 description 11
102000005936 beta-Galactosidase Human genes 0.000 description 11
239000006166 lysate Substances 0.000 description 11
101150069452 z gene Proteins 0.000 description 11
241000711404 Avian avulavirus 1 Species 0.000 description 10
241000283690 Bos taurus Species 0.000 description 10
238000002965 ELISA Methods 0.000 description 10
241000588724 Escherichia coli Species 0.000 description 10
238000001114 immunoprecipitation Methods 0.000 description 10
230000003902 lesion Effects 0.000 description 10
238000003556 assay Methods 0.000 description 9
239000002299 complementary DNA Substances 0.000 description 9
206010022000 influenza Diseases 0.000 description 9
229920002477 rna polymer Polymers 0.000 description 9
108091028043 Nucleic acid sequence Proteins 0.000 description 8
230000002068 genetic effect Effects 0.000 description 8
230000036961 partial effect Effects 0.000 description 8
239000002356 single layer Substances 0.000 description 8
241000712461 unidentified influenza virus Species 0.000 description 8
101100484387 Fowlpox virus FPV127 gene Proteins 0.000 description 7
108010061100 Nucleoproteins Proteins 0.000 description 7
108700026244 Open Reading Frames Proteins 0.000 description 7
108091081024 Start codon Proteins 0.000 description 7
238000010367 cloning Methods 0.000 description 7
238000009396 hybridization Methods 0.000 description 7
230000036039 immunity Effects 0.000 description 7
241000282326 Felis catus Species 0.000 description 6
102000011931 Nucleoproteins Human genes 0.000 description 6
241000286209 Phasianidae Species 0.000 description 6
241000711798 Rabies lyssavirus Species 0.000 description 6
239000000499 gel Substances 0.000 description 6
238000003018 immunoassay Methods 0.000 description 6
210000004962 mammalian cell Anatomy 0.000 description 6
230000010076 replication Effects 0.000 description 6
239000000523 sample Substances 0.000 description 6
238000013519 translation Methods 0.000 description 6
230000014621 translational initiation Effects 0.000 description 6
241000699666 Mus <mouse, genus> Species 0.000 description 5
101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 5
241000287219 Serinus canaria Species 0.000 description 5
238000004458 analytical method Methods 0.000 description 5
238000010276 construction Methods 0.000 description 5
230000003053 immunization Effects 0.000 description 5
230000002458 infectious effect Effects 0.000 description 5
210000003205 muscle Anatomy 0.000 description 5
108091008146 restriction endonucleases Proteins 0.000 description 5
230000000405 serological effect Effects 0.000 description 5
241000894006 Bacteria Species 0.000 description 4
108020004705 Codon Proteins 0.000 description 4
102000002464 Galactosidases Human genes 0.000 description 4
108010093031 Galactosidases Proteins 0.000 description 4
241000238631 Hexapoda Species 0.000 description 4
201000010099 disease Diseases 0.000 description 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
235000013601 eggs Nutrition 0.000 description 4
108020001507 fusion proteins Proteins 0.000 description 4
238000002649 immunization Methods 0.000 description 4
238000007918 intramuscular administration Methods 0.000 description 4
229920001184 polypeptide Polymers 0.000 description 4
244000144977 poultry Species 0.000 description 4
235000013594 poultry meat Nutrition 0.000 description 4
108090000765 processed proteins & peptides Proteins 0.000 description 4
102000004196 processed proteins & peptides Human genes 0.000 description 4
238000010186 staining Methods 0.000 description 4
230000008961 swelling Effects 0.000 description 4
230000003612 virological effect Effects 0.000 description 4
OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 3
241000282472 Canis lupus familiaris Species 0.000 description 3
201000004624 Dermatitis Diseases 0.000 description 3
101150039660 HA gene Proteins 0.000 description 3
241000700721 Hepatitis B virus Species 0.000 description 3
241000282412 Homo Species 0.000 description 3
238000012300 Sequence Analysis Methods 0.000 description 3
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
230000003321 amplification Effects 0.000 description 3
208000010668 atopic eczema Diseases 0.000 description 3
230000005540 biological transmission Effects 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
239000008280 blood Substances 0.000 description 3
239000013592 cell lysate Substances 0.000 description 3
230000002490 cerebral effect Effects 0.000 description 3
238000003776 cleavage reaction Methods 0.000 description 3
230000000295 complement effect Effects 0.000 description 3
230000000120 cytopathologic effect Effects 0.000 description 3
238000010790 dilution Methods 0.000 description 3
239000012895 dilution Substances 0.000 description 3
210000002950 fibroblast Anatomy 0.000 description 3
238000010166 immunofluorescence Methods 0.000 description 3
230000001506 immunosuppresive effect Effects 0.000 description 3
238000011065 in-situ storage Methods 0.000 description 3
210000001161 mammalian embryo Anatomy 0.000 description 3
238000013507 mapping Methods 0.000 description 3
239000003550 marker Substances 0.000 description 3
239000012528 membrane Substances 0.000 description 3
239000000203 mixture Substances 0.000 description 3
238000003199 nucleic acid amplification method Methods 0.000 description 3
230000037361 pathway Effects 0.000 description 3
239000002243 precursor Substances 0.000 description 3
230000007017 scission Effects 0.000 description 3
238000010561 standard procedure Methods 0.000 description 3
238000006467 substitution reaction Methods 0.000 description 3
238000003786 synthesis reaction Methods 0.000 description 3
210000001519 tissue Anatomy 0.000 description 3
101150110188 30 gene Proteins 0.000 description 2
208000030507 AIDS Diseases 0.000 description 2
102000002260 Alkaline Phosphatase Human genes 0.000 description 2
108020004774 Alkaline Phosphatase Proteins 0.000 description 2
108091003079 Bovine Serum Albumin Proteins 0.000 description 2
101100333573 Bovine leukemia virus env gene Proteins 0.000 description 2
241000283707 Capra Species 0.000 description 2
241000282693 Cercopithecidae Species 0.000 description 2
206010011703 Cyanosis Diseases 0.000 description 2
230000004543 DNA replication Effects 0.000 description 2
102100027723 Endogenous retrovirus group K member 6 Rec protein Human genes 0.000 description 2
101710121417 Envelope glycoprotein Proteins 0.000 description 2
208000032843 Hemorrhage Diseases 0.000 description 2
241000255777 Lepidoptera Species 0.000 description 2
101150118742 NP gene Proteins 0.000 description 2
206010033799 Paralysis Diseases 0.000 description 2
241001494479 Pecora Species 0.000 description 2
102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 2
108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 2
102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 2
108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 2
101710182846 Polyhedrin Proteins 0.000 description 2
241000700159 Rattus Species 0.000 description 2
108020004511 Recombinant DNA Proteins 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
238000002105 Southern blotting Methods 0.000 description 2
101150003725 TK gene Proteins 0.000 description 2
108091023040 Transcription factor Proteins 0.000 description 2
102000040945 Transcription factor Human genes 0.000 description 2
241000700647 Variola virus Species 0.000 description 2
150000001413 amino acids Chemical class 0.000 description 2
VEZXCJBBBCKRPI-UHFFFAOYSA-N beta-propiolactone Chemical compound O=C1CCO1 VEZXCJBBBCKRPI-UHFFFAOYSA-N 0.000 description 2
208000034158 bleeding Diseases 0.000 description 2
230000000740 bleeding effect Effects 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
210000003837 chick embryo Anatomy 0.000 description 2
238000012790 confirmation Methods 0.000 description 2
210000004748 cultured cell Anatomy 0.000 description 2
238000005520 cutting process Methods 0.000 description 2
210000000805 cytoplasm Anatomy 0.000 description 2
230000034994 death Effects 0.000 description 2
231100000517 death Toxicity 0.000 description 2
239000007857 degradation product Substances 0.000 description 2
238000011161 development Methods 0.000 description 2
230000018109 developmental process Effects 0.000 description 2
230000000694 effects Effects 0.000 description 2
210000002257 embryonic structure Anatomy 0.000 description 2
238000005516 engineering process Methods 0.000 description 2
230000001815 facial effect Effects 0.000 description 2
239000012091 fetal bovine serum Substances 0.000 description 2
230000004927 fusion Effects 0.000 description 2
102000037865 fusion proteins Human genes 0.000 description 2
230000005847 immunogenicity Effects 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
230000001965 increasing effect Effects 0.000 description 2
210000003292 kidney cell Anatomy 0.000 description 2
239000000463 material Substances 0.000 description 2
238000002703 mutagenesis Methods 0.000 description 2
231100000350 mutagenesis Toxicity 0.000 description 2
238000006386 neutralization reaction Methods 0.000 description 2
102000039446 nucleic acids Human genes 0.000 description 2
108020004707 nucleic acids Proteins 0.000 description 2
150000007523 nucleic acids Chemical class 0.000 description 2
229920002401 polyacrylamide Polymers 0.000 description 2
229960000380 propiolactone Drugs 0.000 description 2
230000001681 protective effect Effects 0.000 description 2
230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 2
230000003362 replicative effect Effects 0.000 description 2
238000011160 research Methods 0.000 description 2
210000001995 reticulocyte Anatomy 0.000 description 2
102220201851 rs143406017 Human genes 0.000 description 2
208000024891 symptom Diseases 0.000 description 2
230000005030 transcription termination Effects 0.000 description 2
230000002103 transcriptional effect Effects 0.000 description 2
230000009466 transformation Effects 0.000 description 2
230000029812 viral genome replication Effects 0.000 description 2
229960004854 viral vaccine Drugs 0.000 description 2
239000005723 virus inoculator Substances 0.000 description 2
239000007762 w/o emulsion Substances 0.000 description 2
230000003442 weekly effect Effects 0.000 description 2
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
235000006576 Althaea officinalis Nutrition 0.000 description 1
241000670670 Amsacta Species 0.000 description 1
IJYZHIOOBGIINM-WDSKDSINSA-N Arg-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@@H](N)CCCN=C(N)N IJYZHIOOBGIINM-WDSKDSINSA-N 0.000 description 1
241001203868 Autographa californica Species 0.000 description 1
102100021935 C-C motif chemokine 26 Human genes 0.000 description 1
102100034871 C-C motif chemokine 8 Human genes 0.000 description 1
201000006082 Chickenpox Diseases 0.000 description 1
108020004638 Circular DNA Proteins 0.000 description 1
241000254173 Coleoptera Species 0.000 description 1
241000272201 Columbiformes Species 0.000 description 1
229920000742 Cotton Polymers 0.000 description 1
UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
238000012286 ELISA Assay Methods 0.000 description 1
241000701832 Enterobacteria phage T3 Species 0.000 description 1
241000700572 Entomopoxvirinae Species 0.000 description 1
241000567413 Estigmene Species 0.000 description 1
241000567412 Estigmene acrea Species 0.000 description 1
241000206602 Eukaryota Species 0.000 description 1
241000282324 Felis Species 0.000 description 1
108700039691 Genetic Promoter Regions Proteins 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
108060003393 Granulin Proteins 0.000 description 1
101000897493 Homo sapiens C-C motif chemokine 26 Proteins 0.000 description 1
101000946794 Homo sapiens C-C motif chemokine 8 Proteins 0.000 description 1
241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
206010061598 Immunodeficiency Diseases 0.000 description 1
208000029462 Immunodeficiency disease Diseases 0.000 description 1
HHSJMSCOLJVTCX-ZDLURKLDSA-N L-Glutaminyl-L-threonine Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@@H](N)CCC(N)=O HHSJMSCOLJVTCX-ZDLURKLDSA-N 0.000 description 1
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
125000003798 L-tyrosyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C([H])([H])C1=C([H])C([H])=C(O[H])C([H])=C1[H] 0.000 description 1
241000721696 Lymantria Species 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
239000000020 Nitrocellulose Substances 0.000 description 1
108010089610 Nuclear Proteins Proteins 0.000 description 1
101710163270 Nuclease Proteins 0.000 description 1
241000238814 Orthoptera Species 0.000 description 1
241000287127 Passeridae Species 0.000 description 1
108010076039 Polyproteins Proteins 0.000 description 1
208000027954 Poultry disease Diseases 0.000 description 1
244000294611 Punica granatum Species 0.000 description 1
206010037888 Rash pustular Diseases 0.000 description 1
206010039509 Scab Diseases 0.000 description 1
241000287181 Sturnus vulgaris Species 0.000 description 1
101800001271 Surface protein Proteins 0.000 description 1
206010042674 Swelling Diseases 0.000 description 1
108010008038 Synthetic Vaccines Proteins 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
206010046980 Varicella Diseases 0.000 description 1
108700005077 Viral Genes Proteins 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
239000002253 acid Substances 0.000 description 1
208000002552 acute disseminated encephalomyelitis Diseases 0.000 description 1
230000002730 additional effect Effects 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
239000011543 agarose gel Substances 0.000 description 1
238000000246 agarose gel electrophoresis Methods 0.000 description 1
238000000137 annealing Methods 0.000 description 1
230000005875 antibody response Effects 0.000 description 1
230000002238 attenuated effect Effects 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
239000000872 buffer Substances 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
239000013553 cell monolayer Substances 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
210000003555 cloaca Anatomy 0.000 description 1
230000002860 competitive effect Effects 0.000 description 1
230000001010 compromised effect Effects 0.000 description 1
229940028617 conventional vaccine Drugs 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
230000008034 disappearance Effects 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
230000004064 dysfunction Effects 0.000 description 1
238000001976 enzyme digestion Methods 0.000 description 1
230000008029 eradication Effects 0.000 description 1
210000003527 eukaryotic cell Anatomy 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
239000012894 fetal calf serum Substances 0.000 description 1
210000002683 foot Anatomy 0.000 description 1
230000008014 freezing Effects 0.000 description 1
238000007710 freezing Methods 0.000 description 1
101150036031 gD gene Proteins 0.000 description 1
150000008195 galaktosides Chemical class 0.000 description 1
230000036449 good health Effects 0.000 description 1
230000012010 growth Effects 0.000 description 1
230000012447 hatching Effects 0.000 description 1
108010077284 hepatitis B surface antigen presurface protein 2 Proteins 0.000 description 1
230000005745 host immune response Effects 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
208000026278 immune system disease Diseases 0.000 description 1
230000007813 immunodeficiency Effects 0.000 description 1
238000007901 in situ hybridization Methods 0.000 description 1
229940031551 inactivated vaccine Drugs 0.000 description 1
125000001041 indolyl group Chemical group 0.000 description 1
230000008595 infiltration Effects 0.000 description 1
238000001764 infiltration Methods 0.000 description 1
229960003971 influenza vaccine Drugs 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
230000010354 integration Effects 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
238000002955 isolation Methods 0.000 description 1
240000001854 junco Species 0.000 description 1
230000002045 lasting effect Effects 0.000 description 1
210000005265 lung cell Anatomy 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
229960004452 methionine Drugs 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
230000035772 mutation Effects 0.000 description 1
210000004237 neck muscle Anatomy 0.000 description 1
239000013642 negative control Substances 0.000 description 1
230000001613 neoplastic effect Effects 0.000 description 1
230000003472 neutralizing effect Effects 0.000 description 1
229920001220 nitrocellulos Polymers 0.000 description 1
230000037311 normal skin Effects 0.000 description 1
238000007899 nucleic acid hybridization Methods 0.000 description 1
230000002611 ovarian Effects 0.000 description 1
239000002245 particle Substances 0.000 description 1
230000007170 pathology Effects 0.000 description 1
230000000149 penetrating effect Effects 0.000 description 1
230000002688 persistence Effects 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
239000013600 plasmid vector Substances 0.000 description 1
230000000644 propagated effect Effects 0.000 description 1
238000000746 purification Methods 0.000 description 1
208000029561 pustule Diseases 0.000 description 1
229940124551 recombinant vaccine Drugs 0.000 description 1
238000011084 recovery Methods 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
238000011076 safety test Methods 0.000 description 1
210000003079 salivary gland Anatomy 0.000 description 1
230000018040 scab formation Effects 0.000 description 1
238000012216 screening Methods 0.000 description 1
238000010517 secondary reaction Methods 0.000 description 1
208000017520 skin disease Diseases 0.000 description 1
206010040882 skin lesion Diseases 0.000 description 1
231100000444 skin lesion Toxicity 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
230000007480 spreading Effects 0.000 description 1
238000003892 spreading Methods 0.000 description 1
230000001629 suppression Effects 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
239000000725 suspension Substances 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
230000002123 temporal effect Effects 0.000 description 1
210000000966 temporal muscle Anatomy 0.000 description 1
238000010257 thawing Methods 0.000 description 1
238000004448 titration Methods 0.000 description 1
210000003371 toe Anatomy 0.000 description 1
230000001256 tonic effect Effects 0.000 description 1
210000003437 trachea Anatomy 0.000 description 1
238000001890 transfection Methods 0.000 description 1
238000012546 transfer Methods 0.000 description 1
230000010474 transient expression Effects 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
210000000689 upper leg Anatomy 0.000 description 1
230000017613 viral reproduction Effects 0.000 description 1
239000013603 viral vector Substances 0.000 description 1
238000005406 washing Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24041—Use of virus, viral particle or viral elements as a vector
- C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
- C12N2760/18122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20111—Lyssavirus, e.g. rabies virus
- C12N2760/20122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Virology (AREA)
Genetics & Genomics (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
Molecular Biology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
Biotechnology (AREA)
Oncology (AREA)
Biomedical Technology (AREA)
Wood Science & Technology (AREA)
Biochemistry (AREA)
Zoology (AREA)
Biophysics (AREA)
General Engineering & Computer Science (AREA)
Communicable Diseases (AREA)
Bioinformatics & Cheminformatics (AREA)
Microbiology (AREA)
Plant Pathology (AREA)
Hematology (AREA)
Physics & Mathematics (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

JP50771588A 1987-08-28 1988-08-24 組換えアビポックスウィルス Expired - Lifetime JP3348156B2 (ja)

Applications Claiming Priority (8)

Application Number	Priority Date	Filing Date
US9071187A	1987-08-28	1987-08-28
US11033587A	1987-10-20	1987-10-20
US110,335		1987-10-20
US18605488A	1988-04-25	1988-04-25
US186,054		1988-04-25
US23439088A	1988-08-23	1988-08-23
US090,711		1988-08-23
US234,390		1988-08-23

Related Child Applications (2)

Application Number	Title	Priority Date	Filing Date
JP2001311076A Division JP2002186494A (ja)	1987-08-28	2001-10-09	組換えワクシニアウイルス
JP2002071416A Division JP3826055B2 (ja)	1987-08-28	2002-03-15	組換えアビポックスウイルスによる免疫方法

Publications (2)

Publication Number	Publication Date
JPH02500879A JPH02500879A (ja)	1990-03-29
JP3348156B2 true JP3348156B2 (ja)	2002-11-20

Family

ID=27492413

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
JP50771588A Expired - Lifetime JP3348156B2 (ja)	1987-08-28	1988-08-24	組換えアビポックスウィルス
JP2001311076A Pending JP2002186494A (ja)	1987-08-28	2001-10-09	組換えワクシニアウイルス
JP2002071416A Expired - Lifetime JP3826055B2 (ja)	1987-08-28	2002-03-15	組換えアビポックスウイルスによる免疫方法

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
JP2001311076A Pending JP2002186494A (ja)	1987-08-28	2001-10-09	組換えワクシニアウイルス
JP2002071416A Expired - Lifetime JP3826055B2 (ja)	1987-08-28	2002-03-15	組換えアビポックスウイルスによる免疫方法

Country Status (17)

Country	Link
JP (3)	JP3348156B2 (fr)
KR (1)	KR970011149B1 (fr)
AR (1)	AR241939A1 (fr)
AT (1)	AT408549B (fr)
AU (2)	AU2427588A (fr)
BE (1)	BE1002134A5 (fr)
CH (2)	CH679933A5 (fr)
DE (4)	DE10399031I1 (fr)
DK (1)	DK175904B1 (fr)
FR (1)	FR2621487B1 (fr)
GB (1)	GB2217718B (fr)
IL (1)	IL87581A0 (fr)
IT (1)	IT1229484B (fr)
LU (2)	LU90951I2 (fr)
NL (4)	NL195051C (fr)
NZ (1)	NZ225970A (fr)
WO (1)	WO1989003429A1 (fr)

Families Citing this family (116)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5338683A (en) *	1981-12-24	1994-08-16	Health Research Incorporated	Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins
US5505941A (en) *	1981-12-24	1996-04-09	Health Research, Inc.	Recombinant avipox virus and method to induce an immune response
US7045313B1 (en)	1982-11-30	2006-05-16	The United States Of America As Represented By The Department Of Health And Human Services	Recombinant vaccinia virus containing a chimeric gene having foreign DNA flanked by vaccinia regulatory DNA
DE10399031I1 (de) *	1987-08-28	2004-01-29	Health Research Inc	Rekombinante Viren.
US5286639A (en) *	1987-09-16	1994-02-15	Nippon Zeon Co., Ltd.	Recombinant avipoxvirus
DE3813093A1 (de) *	1988-04-19	1989-11-09	Immuno Ag	Rekombinantes plasmid, verfahren zum herstellen eines rekombinanten avipoxvirus, rekombinantes avipoxvirus und dessen verwendung
US5631154A (en) *	1988-06-10	1997-05-20	Therion Biologics, Incorporated	Self assembled, defective, non-self-propagating lentivirus particles
EP0353851B1 (fr) *	1988-06-24	1994-01-19	Btg International Limited	Régions non essentielles du virus du fowlpox
US5093258A (en) *	1988-08-26	1992-03-03	Therion Biologics Corporation	Recombinant fowlpox virus and recombination vector
CA2001001A1 (fr) *	1988-10-21	1990-04-21	Matthew M. Binns	Promoteur du virus de l'acne molluscum
US6248333B1 (en)	1990-04-04	2001-06-19	Health Research Inc.	Isolated nucleic acid sequence of equine herpesvirus type 1 glycoprotein D (EHV-1 gD)
US5204243A (en) *	1990-02-14	1993-04-20	Health Research Incorporated	Recombinant poxvirus internal cores
MY109299A (en) *	1990-08-15	1996-12-31	Virogenetics Corp	Recombinant pox virus encoding flaviviral structural proteins
US5514375A (en) *	1990-08-15	1996-05-07	Virogenetics Corporation	Flavivirus recombinant poxvirus vaccine
FR2668064B1 (fr) *	1990-10-23	1994-12-16	Transgene Sa	Composition pharmaceutique pour le traitement ou la prevention d'une tumeur maligne.
US5759841A (en) *	1990-11-20	1998-06-02	Virogenetics Corporation	Immunological composition of measles virus utilizing recombinant poxvirus
US5503834A (en) *	1990-11-20	1996-04-02	Virogenetics Corporation	Measles virus recombinant poxvirus vaccine
IE68404B1 (en) *	1990-11-20	1996-06-12	Virogenetics Corp	Measles virus recombinant poxvirus vaccine
US5756102A (en) *	1990-11-20	1998-05-26	Virogenetics Corporation	Poxvirus-canine distemper virus (CDV) recombinants and compositions and methods employing the recombinants
US6309647B1 (en)	1999-07-15	2001-10-30	Aventis Pasteur	Poxvirus—canine dispemper virus (CDV) or measles virus recombinants and compositions and methods employing the recombinants
US5338679A (en) *	1991-01-08	1994-08-16	Her Majesty The Queen In Right Of Canada, As Represented By National Research Council Canada And Forestry Canada	Vertebrate poxvoris expression vector under the control of entomopoxvirus spheroidin gene promoter
KR100242671B1 (ko) *	1991-03-07	2000-03-02	고돈 에릭	유전학적으로 처리한 백신 균주
US5766598A (en) *	1991-03-07	1998-06-16	Virogenetics Corporation	Recombinant attenuated ALVAC canarypoxvirus expression vectors containing heterologous DNA segments encoding lentiviral gene products
AU672581B2 (en) *	1991-03-07	1996-10-10	Virogenetics Corporation	Immunodeficiency virus recombinant poxvirus vaccine
US5863542A (en) *	1991-03-07	1999-01-26	Virogenetics Corporation	Recombinant attenuated ALVAC canaryopox virus containing heterologous HIV or SIV inserts
US5756101A (en) *	1991-07-01	1998-05-26	Pasteur Merieux Serums Et Vaccins	Malaria recombinant poxvirus
US5766597A (en) *	1991-03-07	1998-06-16	Virogenetics Corporation	Malaria recombinant poxviruses
JPH06505397A (ja) *	1991-03-20	1994-06-23	ヴァイロジェネティクス　コーポレイション	マラリア組換体ポックスウイルス
JPH06509235A (ja) *	1991-07-26	1994-10-20	ヴァイロジェネティクス　コーポレイション	伝染性ファブリキウス嚢病ウイルス組換えポックスウイルスワクチン
EP1380651A2 (fr) *	1991-08-26	2004-01-14	Baxter Healthcare S.A.	Virus de la variole aviaire recombinant comportant un gène PFPV-tk intact
US5443831A (en) *	1991-10-29	1995-08-22	University Of Delaware	Gene encoding glycoprotein B of Infectious Laryngotracheitis Virus
US6497882B1 (en)	1992-01-13	2002-12-24	Syntro Corporation	Recombinant swinepox virus
US6328975B1 (en)	1992-01-13	2001-12-11	Syntro Corporation	Recombinant swinepox virus
ES2236684T3 (es) *	1992-01-13	2005-07-16	Virogenetics Corporation	Vacuna del virus vaccinia recombinante procedente del virus de la enfermedad de marek.
US5869312A (en) *	1992-01-13	1999-02-09	Syntro Corporation	Recombinant swinepox virus
US6033904A (en) *	1992-01-13	2000-03-07	Syntro Corporation	Recombinant swinepox virus
US6251403B1 (en)	1992-01-13	2001-06-26	Syntro Corporation	Recombinant swinepox virus
US6127163A (en) *	1992-01-13	2000-10-03	Syntro Corporation	Recombinant swinepox virus
EP0662139A1 (fr) *	1992-09-21	1995-07-12	Chiron Corporation	Vecteur retroviral recombine contre le virus de la leucemie feline et/ou le virus de l'immunodeficience feline
US6136318A (en) *	1993-02-26	2000-10-24	Cochran; Mark D.	Recombinant fowlpox viruses and uses thereof
AU727278B2 (en) *	1993-02-26	2000-12-07	Syntro Corporation	Recombinant fowlpox viruses and uses thereof II
US5925358A (en) *	1993-02-26	1999-07-20	Syntro Corporation	Recombinant fowlpox viruses and uses thereof
AU6299594A (en) *	1993-02-26	1994-09-14	Nippon Zeon Co., Ltd.	Recombinant fowlpox virus s-fpv-043 and uses thereof
US5496731A (en) *	1993-03-25	1996-03-05	Xu; Hong-Ji	Broad-spectrum tumor suppressor genes, gene products and methods for tumor suppressor gene therapy
US5843742A (en) *	1994-12-16	1998-12-01	Avigen Incorporated	Adeno-associated derived vector systems for gene delivery and integration into target cells
EP0753581A1 (fr)	1995-07-10	1997-01-15	Immuno Ag	Virus recombinantes eucaryotes cytoplasmiques améliorés, un procédé pour leur préparation et leur utilisation comme vaccins
US5858373A (en) *	1995-12-01	1999-01-12	Virogenetics Corporation	Recombinant poxvirus-feline infectious peritionitis virus, compositions thereof and methods for making and using them
CA2261989C (fr)	1996-07-25	2008-09-30	Therion Biologics Corporation	Poxvirus recombinant pour l'immunisation contre des antigenes associes aux tumeurs
US6106825A (en) *	1997-05-07	2000-08-22	University Of Florida	Entomopoxvirus-vertebrate gene delivery vector and method
WO1999007869A1 (fr) *	1997-08-05	1999-02-18	University Of Florida	Vaccin vivant recombinant comprenant un virus ne se repliquant pas ou se repliquant sans efficacite
US6248582B1 (en) *	1997-10-08	2001-06-19	Imran Khan	Gene deleted recombinant FeLV proviral DNA for production of vaccines against FeLV
JPH11165762A (ja)	1997-12-01	1999-06-22	Lintec Corp	チップ体搬送用カバーテープおよび封止構造体
US20020147143A1 (en)	1998-03-18	2002-10-10	Corixa Corporation	Compositions and methods for the therapy and diagnosis of lung cancer
US20030235557A1 (en)	1998-09-30	2003-12-25	Corixa Corporation	Compositions and methods for WT1 specific immunotherapy
US6200560B1 (en)	1998-10-20	2001-03-13	Avigen, Inc.	Adeno-associated virus vectors for expression of factor VIII by target cells
US6221349B1 (en)	1998-10-20	2001-04-24	Avigen, Inc.	Adeno-associated vectors for expression of factor VIII by target cells
US7935805B1 (en)	1998-12-31	2011-05-03	Novartis Vaccines & Diagnostics, Inc	Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
CA2360347C (fr)	1998-12-31	2013-05-07	Chiron Corporation	Expression amelioree de polypeptides hiv et production de particules de type viral
CN1379819A (zh)	1999-06-28	2002-11-13	俄克拉荷马州医学研究基金会	具有催化活性的重组memapsin蛋白酶及其应用方法
CA2400842C (fr)	2000-02-23	2013-01-15	Smithkline Beecham Biologicals S.A.	Nouveaux composes
WO2002000174A2 (fr)	2000-06-28	2002-01-03	Corixa Corporation	Compositions et methodes pour le traitement et le diagnostic du cancer du poumon
DE60239317D1 (de)	2001-01-12	2011-04-14	Novartis Vaccines & Diagnostic	Nukleinsäure mukosale immunisierung
PT1370668E (pt) *	2001-03-08	2006-06-30	Akzo Nobel Nv	Vacinas de vector baseadas em leporipox
JP4499311B2 (ja) *	2001-04-27	2010-07-07	シャープ株式会社	放送受信端末
EP1988097A1 (fr)	2001-05-09	2008-11-05	Corixa Corporation	Compositions et procédés pour le traitement et le diagnostic du cancer de la prostate
AU2002320314A1 (en)	2001-07-05	2003-01-21	Chiron, Corporation	Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
EP1409694A4 (fr)	2001-07-05	2006-02-08	Chiron Corp	Polynucleotides codant pour des polypeptides antigeniques du vih de sous-type b et/ou de sous-type c, polypeptides et leurs utilisations
WO2003053220A2 (fr)	2001-12-17	2003-07-03	Corixa Corporation	Compositions et procedes applicables a la therapie et au diagnostic pour la maladie intestinale inflammatoire
HUE026376T2 (en)	2003-01-06	2016-05-30	Corixa Corp	Certain aminoalkyl glucosamide phosphate compounds and their use
US7960522B2 (en)	2003-01-06	2011-06-14	Corixa Corporation	Certain aminoalkyl glucosaminide phosphate compounds and their use
US20070073048A1 (en)	2003-05-15	2007-03-29	Ying Lian	Hiv polynucleotides and polypeptides derived from botswana mj4
US7261882B2 (en)	2003-06-23	2007-08-28	Reagents Of The University Of Colorado	Methods for treating neuropathic pain by administering IL-10 polypeptides
EP2305294B1 (fr)	2004-09-22	2015-04-01	GlaxoSmithKline Biologicals SA	Composition immunogène pour la vaccination contre des staphylocoques
WO2007081447A2 (fr)	2005-11-22	2007-07-19	Novartis Vaccines And Diagnostics, Inc.	Antigènes de norovirus et de sapovirus
CA2636424A1 (fr)	2006-01-09	2007-10-25	The Regents Of The University Of California	Combinaisons immunostimulantes de tnfrsf, tlr, nlr, rhr, recepteurs purinergiques et d'agonistes des recepteurs de cytokines pour vaccins et immunotherapie contre les tumeurs
EP2397856B1 (fr)	2006-03-14	2013-11-13	Oregon Health and Science University	Procédés pour détecter une infection de tuberculose à mycobactérie
US8188214B2 (en)	2007-02-28	2012-05-29	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Brachyury polypeptides and methods for use
WO2009049351A1 (fr)	2007-10-15	2009-04-23	The University Of Queensland	Système de construction et utilisations pour celui-ci
US8691502B2 (en)	2008-10-31	2014-04-08	Tremrx, Inc.	T-cell vaccination with viral vectors via mechanical epidermal disruption
AU2010203223B9 (en)	2009-01-05	2015-10-08	Epitogenesis Inc.	Adjuvant compositions and methods of use
WO2010099472A2 (fr)	2009-02-27	2010-09-02	The U.S.A. Of America, As Represented By The Secretary, Department Of Health And Human Services	Polypeptides spanx-b et leur utilisation
US8961989B2 (en)	2009-11-20	2015-02-24	Oregon Health & Science University	Methods for producing an immune response to tuberculosis
WO2011106705A2 (fr)	2010-02-26	2011-09-01	The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Protocoles de vaccination adn/protéine
US9795658B2 (en)	2010-04-20	2017-10-24	Admedus Vaccines Pty Ltd	Expression system for modulating an immune response
US9428565B2 (en)	2011-01-31	2016-08-30	The General Hospital Corporation	Treatment and bioluminescent visualization using multimodal TRAIL molecules
WO2012151272A2 (fr)	2011-05-02	2012-11-08	Tremrx, Inc.	Vaccination avec des lymphocytes t à l'aide de vecteurs viraux par rupture épidermique mécanique
US20150030586A1 (en)	2011-06-21	2015-01-29	Sarah Ellen Warren	Compositions and methods for the therapy and diagnosis of cancer
BR112013032410A2 (pt)	2011-06-24	2017-01-17	Epitogenesis Inc	composições farmacêuticas compreendendo uma combinação de veículos, vitaminas, taninos e flavonoides de seleção como imunomoduladores específicos de antígeno
US20150004144A1 (en)	2011-12-02	2015-01-01	The General Hospital Corporation	Differentiation into brown adipocytes
US9605074B2 (en)	2012-08-30	2017-03-28	The General Hospital Corporation	Multifunctional nanobodies for treating cancer
WO2014043535A1 (fr)	2012-09-14	2014-03-20	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Compositions destinées à traiter le cancer
ES2752190T3 (es)	2012-09-14	2020-04-03	Us Health	Proteína Brachyury, vectores adenovirales que codifican proteína Brachyury y su uso
SG10201912901YA (en)	2013-04-17	2020-02-27	Genzyme Corp	Compositions and methods for treating and preventing macular degeneration
AU2014268603B2 (en)	2013-05-21	2018-03-22	President And Fellows Of Harvard College	Engineered heme-binding compositions and uses thereof
US10172916B2 (en)	2013-11-15	2019-01-08	The Board Of Trustees Of The Leland Stanford Junior University	Methods of treating heart failure with agonists of hypocretin receptor 2
CA2938828A1 (fr)	2014-02-06	2015-08-13	Genzyme Corporation	Compositions et methodes de traitement et de prevention de la degenerescence maculaire
JP7095990B2 (ja)	2014-09-18	2022-07-05	シーダーズ－サイナイメディカルセンター	線維症を治療するための組成物及び方法
JP2018511655A (ja)	2015-03-20	2018-04-26	ザリージェンツオブザユニバーシティオブミシガン	ボルデテラ属に対するワクチン接種における使用のための免疫原性組成物
EP3283529B1 (fr)	2015-04-17	2023-06-07	The General Hospital Corporation	Agents, systèmes et méthodes de traitement du cancer
CN107708718B (zh)	2015-04-22	2022-01-11	西达-赛奈医疗中心	用于治疗2型糖尿病的肠内递送的苦味寡肽
EP4276106A3 (fr)	2015-05-13	2024-01-24	The United States of America as represented by the Secretary of the Department of Health and Human Services	Methodes et compositions pour eliciter des reponses immune a base des constructs contenant des elements conservatives
WO2016196366A1 (fr)	2015-05-29	2016-12-08	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Extension de durée de vie réplicative dans des maladies de vieillissement prématuré à l'aide d'isoformes p53
EP3313863B1 (fr)	2015-06-29	2020-12-23	The Board of Trustees of the Leland Stanford Junior University	Constructions de fusion de degron et procédés de régulation de la production de protéine
EP3386593A4 (fr)	2015-12-09	2019-07-24	Admedus Vaccines Pty Ltd	Composition immunomodulatrice pour le traitement
WO2018018082A1 (fr)	2016-07-26	2018-02-01	The Australian National University	Compositions immunostimulantes et utilisations de celles-ci
US10917454B1 (en)	2019-08-01	2021-02-09	Rohde & Schwarz Gmbh & Co. Kg	System and method for ATC voice quality assurance
WO2023070072A1 (fr)	2021-10-21	2023-04-27	The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone	Leurres de facteur de transcription générés par rétro-éléments
WO2023077147A2 (fr)	2021-11-01	2023-05-04	Pellis Therapeutics, Inc.	Vaccins à lymphocytes t pour patients présentant une immunité humorale réduite
WO2023081756A1 (fr)	2021-11-03	2023-05-11	The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone	Édition précise du génome à l'aide de rétrons
WO2023141602A2 (fr)	2022-01-21	2023-07-27	Renagade Therapeutics Management Inc.	Rétrons modifiés et méthodes d'utilisation
WO2023183589A1 (fr)	2022-03-25	2023-09-28	The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone	Édition génomique à fidélité de rt-adn et à rétrons
WO2023183588A1 (fr)	2022-03-25	2023-09-28	The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone	Procédés d'évaluation de l'activité rétronique modifiée et leurs utilisations
WO2023183627A1 (fr)	2022-03-25	2023-09-28	The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone	Production d'adn transcrit inversé (adn-rt) au moyen d'une rétron transcriptase inverse à partir d'adn exogène
WO2024020346A2 (fr)	2022-07-18	2024-01-25	Renagade Therapeutics Management Inc.	Composants d'édition génique, systèmes et procédés d'utilisation
WO2024044673A1 (fr)	2022-08-24	2024-02-29	The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone	Éditeurs de rétron à double coupe pour insertions et délétions génomiques
WO2024044723A1 (fr)	2022-08-25	2024-02-29	Renagade Therapeutics Management Inc.	Rétrons modifiés et méthodes d'utilisation

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK489481A (da) *	1980-11-10	1982-05-11	Searle & Co	Plasmidvektor og frmgangsmaade til fremstilling deraf
US4603112A (en) *	1981-12-24	1986-07-29	Health Research, Incorporated	Modified vaccinia virus
JPH0795954B2 (ja) *	1982-11-30	1995-10-18	アメリカ合衆国	外来性遺伝子発現のためのポックスウイルス組換え体の製造方法
FR2563434B1 (fr) *	1984-04-25	1986-07-25	Transgene Sa	Vaccin contre la rage et procede pour sa preparation
EP0190254A4 (fr) *	1984-07-05	1987-03-09	Genex Corp	Gene clone et son procede de preparation et d'utilisation.
DD235669A1 (de) *	1985-03-26	1986-05-14	Akad Wissenschaften Ddr	Verfahren zur herstellung eines blv-kodierten huellproteins
US5032520A (en) *	1985-03-29	1991-07-16	National Research Development Corporation	DNA sequences encoding infectious bronchitis virus spike protein
EP0213894A3 (fr) *	1985-08-23	1987-10-21	Advanced Genetics Research Institute	Vaccins à particules virales imparfaites et méthodes d'utilisation
AU607399B2 (en) *	1985-09-09	1991-03-07	Cetus Corporation	Infectious recombinant virus vaccine for feline leukemia
GR862412B (en) *	1985-09-25	1987-01-23	Oncogen	Vaccines and immuinoassays for acquired immune deficiency syndrome
AU602875B2 (en) *	1985-12-18	1990-11-01	British Technology Group Limited	Newcastle disease virus gene clones
AU8075787A (en) *	1986-09-22	1988-04-07	Australian National University, The	Recombinant poxviruses
WO1988002022A1 (fr) *	1986-09-22	1988-03-24	Commonwealth Scientific And Industrial Research Or	Virus de la variole recombinant
EP0261940A3 (fr) *	1986-09-23	1989-07-05	Applied Biotechnology, Inc.	Vaccins pseudorabiques et vecteurs d'ADN pour recombiner avec les poxvirus
EP0284416B1 (fr) *	1987-03-27	1995-02-22	Nippon Zeon Co., Ltd.	Avipoxvirus recombinant
DE10399031I1 (de) *	1987-08-28	2004-01-29	Health Research Inc	Rekombinante Viren.
GB8724885D0 (en) *	1987-10-23	1987-11-25	Binns M M	Fowlpox virus promotors
FR2632863B2 (fr) *	1987-10-29	1990-08-31	Transgene Sa	Virus du fowlpox recombinant et vaccins derives de ces virus
EP0353851B1 (fr) *	1988-06-24	1994-01-19	Btg International Limited	Régions non essentielles du virus du fowlpox
DE4090351T1 (de) *	1989-03-08	1997-07-24	Health Research Inc	Rekombinantes Pockenvirus-Wirtsselektionssystem
EP0550553B1 (fr) *	1990-09-25	2000-07-12	Cantab Pharmaceuticals Research Limited	Vaccin viral mutant a genome deficient et produit en transcomplementant la lignee cellulaire

1987
- 1987-08-24 DE DE2003199031 patent/DE10399031I1/de active Pending
- 1987-08-24 DE DE2003199032 patent/DE10399032I1/de active Pending
1988
- 1988-08-24 KR KR1019890700753A patent/KR970011149B1/ko not_active IP Right Cessation
- 1988-08-24 WO PCT/US1988/002816 patent/WO1989003429A1/fr active Application Filing
- 1988-08-24 DE DE3890874A patent/DE3890874C5/de not_active Expired - Lifetime
- 1988-08-24 CH CH1652/89A patent/CH679933A5/de not_active IP Right Cessation
- 1988-08-24 AU AU24275/88A patent/AU2427588A/en not_active Abandoned
- 1988-08-24 DE DE2002199049 patent/DE10299049I1/de active Pending
- 1988-08-24 AT AT0900788A patent/AT408549B/de not_active IP Right Cessation
- 1988-08-24 CH CH1444/91A patent/CH679934A5/de not_active IP Right Cessation
- 1988-08-24 GB GB8908921A patent/GB2217718B/en not_active Expired - Lifetime
- 1988-08-24 NL NL8820679A patent/NL195051C/nl not_active IP Right Cessation
- 1988-08-24 JP JP50771588A patent/JP3348156B2/ja not_active Expired - Lifetime
- 1988-08-28 IL IL87581A patent/IL87581A0/xx not_active IP Right Cessation
- 1988-08-29 NZ NZ225970A patent/NZ225970A/xx unknown
- 1988-08-29 BE BE8800978A patent/BE1002134A5/fr not_active IP Right Cessation
- 1988-08-29 FR FR888811334A patent/FR2621487B1/fr not_active Expired - Lifetime
- 1988-08-29 IT IT8821772A patent/IT1229484B/it active
- 1988-08-29 AR AR88311787A patent/AR241939A1/es active
1989
- 1989-04-27 DK DK198902036A patent/DK175904B1/da active Protection Beyond IP Right Term
1995
- 1995-04-05 AU AU16288/95A patent/AU690210B2/en not_active Expired
2001
- 2001-10-09 JP JP2001311076A patent/JP2002186494A/ja active Pending
2002
- 2002-03-15 JP JP2002071416A patent/JP3826055B2/ja not_active Expired - Lifetime
- 2002-09-04 LU LU90951C patent/LU90951I2/fr unknown
2003
- 2003-07-09 NL NL300130C patent/NL300130I2/nl unknown
- 2003-09-05 LU LU91039C patent/LU91039I2/fr unknown
- 2003-11-25 NL NL300139C patent/NL300139I1/nl unknown
- 2003-11-25 NL NL300138C patent/NL300138I2/nl unknown

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ＡｖｉａｎＤｉｓｅａｓｅｓ，Ｖｏｌ．３０，Ｎｏ．１，Ｐ．２４−２７
Ｖｉｒｏｌｏｇｙ，Ｖｏｌ．１５６，Ｐ．３５５−３６５（１９８７年３月）
Ｖｉｒｏｌｏｇｙ，Ｖｏｌ．１６０，Ｎｏ．１，（１９８７），Ｐ．２０３−２０９

Also Published As

Publication number	Publication date
FR2621487A1 (fr)	1989-04-14
DE10399031I1 (de)	2004-01-29
WO1989003429A1 (fr)	1989-04-20
DK175904B1 (da)	2005-06-06
AU690210B2 (en)	1998-04-23
JP3826055B2 (ja)	2006-09-27
CH679933A5 (fr)	1992-05-15
NL300138I2 (nl)	2004-03-01
JP2002186494A (ja)	2002-07-02
JPH02500879A (ja)	1990-03-29
NL300130I1 (nl)	2003-09-01
NL195051C (nl)	2003-07-01
CH679934A5 (fr)	1992-05-15
IT8821772A0 (it)	1988-08-29
IT1229484B (it)	1991-09-03
NZ225970A (en)	1991-01-29
AR241939A1 (es)	1993-01-29
GB2217718A (en)	1989-11-01
AU1628895A (en)	1995-08-17
ATA900788A (de)	1995-05-15
DE10399032I1 (de)	2004-01-29
DE3890874C2 (de)	2003-03-13
LU90951I2 (fr)	2003-01-15
DK203689D0 (da)	1989-04-27
KR970011149B1 (ko)	1997-07-07
DE3890874C5 (de)	2005-10-20
NL300130I2 (nl)	2005-11-01
NL8820679A (nl)	1989-07-03
GB2217718B (en)	1992-05-20
LU91039I2 (fr)	2003-11-05
IL87581A0 (en)	1989-01-31
KR890701757A (ko)	1989-12-21
NL300139I1 (nl)	2004-02-02
FR2621487B1 (fr)	1991-10-18
BE1002134A5 (fr)	1990-07-24
NL300138I1 (nl)	2004-02-02
AT408549B (de)	2001-12-27
GB8908921D0 (en)	1989-08-02
JP2002348255A (ja)	2002-12-04
DE10299049I1 (de)	2004-07-01
DK203689A (da)	1989-06-27
AU2427588A (en)	1989-05-02

Legal Events

Date	Code	Title	Description
2005-09-06	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2006-09-05	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2007-09-04	FPAY	Renewal fee payment (event date is renewal date of database)	Free format text: PAYMENT UNTIL: 20080913 Year of fee payment: 6
2008-08-24	EXPY	Cancellation because of completion of term

Publication	Publication Date	Title
JP3348156B2 (ja)	2002-11-20	組換えアビポックスウィルス
US5505941A (en)	1996-04-09	Recombinant avipox virus and method to induce an immune response
US5174993A (en)	1992-12-29	Recombinant avipox virus and immunological use thereof
US5187087A (en)	1993-02-16	Recominbant herpesvirus of turkeys and live vector vaccines derived thereof
JP2002514885A (ja)	2002-05-21	ポックスウイルス−イヌジステンパーウイルス（ｃｄｖ）組み換え体類および組成物類および前記組み換え体類を用いる方法
IT9020063A1 (it)	1991-10-17	Vaccino di poxvirus ricombinante di herpesvirus
JP2007105040A (ja)	2007-04-26	組換体ポックスウイルス−ネコ感染性腹膜炎ウイルス、その組成物およびそれらの製造および使用方法
JP2007082551A (ja)	2007-04-05	組換えポックスウイルス−カリシウイルス［ウサギ出血疾患ウイルス（ｒｈｄｖ）］組成物および使用
US4738846A (en)	1988-04-19	Vaccine for vesicular stomatitis virus
JP2007254489A (ja)	2007-10-04	Ｈｔｌｖ抗原を発現する組換え弱毒化ポックスウイルスを含有する免疫原性組成物
JPH0235079A (ja)	1990-02-05	感染性ウシ鼻気管炎ウイルスの挿入突然変異体
JP3529134B2 (ja)	2004-05-24	組換えネコヘルペスウイルスのベクターワクチン
US5279965A (en)	1994-01-18	Recombinant infectious laryngotracheitis virus
WO2007115385A2 (fr)	2007-10-18	Vecteur plasmidique de transfert et virus canarypox recombinant
AU761321B2 (en)	2003-06-05	Recombinant viruses, vaccines containing them and in vitro cell cultures thereof
CA1341403C (fr)	2002-11-26	Virus de la variole aviaire (avipox) recombinant
AU725985B2 (en)	2000-10-26	Recombinant virus
DK175980B1 (da)	2005-10-24	Recombinante vacciniavira og anvendelsen af samme
DK176068B1 (da)	2006-03-06	Rekombinant kanaripoxvirus og anvendelsen af samme
DK176165B1 (da)	2006-11-06	Rekombinant fjerkræpoxvirus samt anvendelsen af samme
IE60309B1 (en)	1994-06-29	Recombinant viruses, vaccines containing them and in vitro cell cultures thereof